Xalud Therapeutics Overview

  • Year Founded
  • 2009

Year Founded

  • Status
  • Private

  • Employees
  • 19

Employees

  • Latest Deal Type
  • Series C

  • Latest Deal Amount
  • $32.5M

  • Investors
  • 4

Xalud Therapeutics General Information

Description

Developer of a gene therapy platform designed to treat neuroinflammatory diseases. The company's platform creates therapies that use new strategies in pain management that target neuropathic pain effectively and get to the root of the disease, enabling doctors to help patients get relief from inflammatory joint disorders including osteoarthritis and rheumatoid arthritis.

Contact Information

Website
www.xaludthera.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Primary Office
  • 40 West 57th Street
  • Suite 1810
  • New York, NY 10019
  • United States
+1 (212) 000-0000

Xalud Therapeutics Timeline

2020202120222023
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Xalud Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Later Stage VC (Series C) 24-Aug-2021 $32.5M 0000 00000 Completed Clinical Trials - Phase 2
4. Later Stage VC (Series B) 30-Mar-2020 0000 000.00 0000 Completed Clinical Trials - Phase 1
3. Grant 31-Dec-2018 00.000 000.00 Completed Clinical Trials - Phase 1
2. Later Stage VC (Series A) 25-Jun-2015 $11.5M $11.5M 000.00 Completed Clinical Trials - Phase 1
1. Grant 31-Jan-2015 $11M Completed Clinical Trials - Phase 1
To view Xalud Therapeutics’s complete valuation and funding history, request access »

Xalud Therapeutics Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series C 00,000,000 00.000000 00.0 00.0 00 00.0 0.000
Series B 00,000,000 00.000000 00.00 00.00 00 00.00 00.00
Series A 36,838,389 $0.000100 $0.54 $0.54 1x $0.54 34.04%
To view Xalud Therapeutics’s complete cap table history, request access »

Xalud Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a gene therapy platform designed to treat neuroinflammatory diseases. The company's platform creates therap
Biotechnology
New York, NY
19 As of 2023
0000
0000 0000-00-00
00000000000 0000

0000 0

e velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cup
0000 000000000
South San Francisco, CA
00 As of 0000
00000
00000000 00000

000000

cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non pr
0000 000000000
San Diego, CA
000 As of 0000
00000
0000000 0000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Xalud Therapeutics Competitors (4)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Vera Therapeutics Formerly VC-backed South San Francisco, CA 00 00000 00000000 00000
000000000 00000000 Private Equity-Backed San Diego, CA 000 00000 0000000 0000 00000
0000000 0000000 Venture Capital-Backed Waltham, MA 00 000.00 00000000000 000.00
000000 00000000000 Formerly VC-backed Parsippany, NJ 000 00000 000000000 00 00000
To view Xalud Therapeutics’s complete competitors history, request access »

Xalud Therapeutics Patents

  • 10

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 1

    Granted

  • 000

    Pending

  • 000

    Expiring in next 12 mo

Xalud Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2018383773-A1 Halogenated derivatives of morphinans and uses thereof Pending 12-Dec-2017 0000000000
CA-3085321-A1 Halogenated derivatives of morphinans and uses thereof Active 12-Dec-2017 0000000000
EP-3723749-A4 Halogenated derivatives of morphinans and uses thereof Pending 12-Dec-2017 0000000000 0
EP-3723749-A1 Halogenated derivatives of morphinans and uses thereof Pending 12-Dec-2017 0000000000
JP-2021506768-A Halogenated derivatives of morphinan and their use Active 12-Dec-2017 C07D489/00
To view Xalud Therapeutics’s complete patent history, request access »

Xalud Therapeutics Executive Team (13)

Name Title Board Seat Contact Info
Diem Nguyen Ph.D Chief Executive Officer, President & Board Member
Brendan O'Leary Chief Operating Officer & Co-Chief Financial Officer
Charles Triano Co-Chief Financial Officer & Advisor
Kristin Murray Chief Regulatory Officer & Head of Quality
Raymond Chavez Ph.D Co-Founder & Vice President of Research & Development
You’re viewing 5 of 13 executive team members. Get the full list »

Xalud Therapeutics Board Members (8)

Name Representing Role Since
Diem Nguyen Ph.D Xalud Therapeutics Chief Executive Officer, President & Board Member 000 0000
Jayson Rieger Ph.D Self Board Member 000 0000
Linda Watkins Ph.D Xalud Therapeutics Co-Founder & Chairman of Scientific Advisory Board 000 0000
Paul Manning PBM Capital Board Member 000 0000
Sean Stalfort PBM Capital Board Member 000 0000
You’re viewing 5 of 8 board members. Get the full list »

Xalud Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Xalud Therapeutics Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
PBM Capital PE/Buyout Minority 000 0000 000000 0
National institutes of Neurological Disorders and Stroke Government 000 0000 000000 0
United States Department of Defense Government 000 0000 000000 0
U.S. Department of Health and Human Services Government 000 0000 000000 0
To view Xalud Therapeutics’s complete investors history, request access »

Ready to get started?

Request a free trial